Radioactive 'Tumor-Seeking' drug tested to boost cancer surgery success

NCT ID NCT04609592

Summary

This small, early-stage study is testing whether it is safe and practical to give a targeted radioactive treatment (called PRRT) both before and after surgery to remove certain slow-growing digestive tract tumors that have spread. The goal is to see if this combined approach helps control the cancer better and keeps patients living longer. The study will enroll about 10 people with specific types of metastatic neuroendocrine tumors who are already candidates for surgery.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stanford Cancer Institute Palo Alto

    RECRUITING

    Stanford, California, 95304, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.